SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from BioNTech SE (BNTX) (CIK 0001776985) (BNTX) — Feb 3, 2020

BioNTech SE (BNTX) (CIK 0001776985)
Date: Feb. 3, 2020 · CIK: 0001776985 · Accession: 0001193125-20-023027

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-236225

Date
February 3, 2020
Author
BioNTech SE
Form
CORRESP
Company
BioNTech SE (BNTX) (CIK 0001776985)

Letter

BioNTech SE

An der Goldgrube 12

D-55131 Mainz

Germany

February 3, 2020

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3561

Attn: Paul Fischer

Re: BioNTech SE

Registration Statement on Form F-1

Filed February 3, 2020

File No. 333-236225

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), BioNTech SE (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) be accelerated by the U.S. Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on February 5, 2020, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.

We respectfully request that we be notified of such effectiveness by a telephone call to Eric W. Blanchard of Covington & Burling LLP at (212) 841-1111 and that such effectiveness also be confirmed in writing.

Respectfully,
BioNTech SE

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 BioNTech SE

An der Goldgrube 12

 D-55131 Mainz

 Germany

February 3, 2020

 Via
EDGAR

 U.S. Securities and Exchange Commission

 Division
of Corporation Finance

 100 F Street, N.E.

 Washington, D.C.
20549-3561

 Attn: Paul Fischer

Re:
 BioNTech SE

Registration Statement on Form F-1

Filed February 3, 2020

File No. 333-236225

Ladies and Gentlemen:

 Pursuant to Rule 461 under the
Securities Act of 1933, as amended (the “Securities Act”), BioNTech SE (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form
F-1 (the “Registration Statement”) be accelerated by the U.S. Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m.
Eastern Time on February 5, 2020, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.

We respectfully request that we be notified of such effectiveness by a telephone call to Eric W. Blanchard of Covington & Burling LLP at (212) 841-1111 and that such effectiveness also be confirmed in writing.

Respectfully,

BioNTech SE

By:

 /s/ Prof. Ugur Sahin, M.D.

Name:

Prof. Ugur Sahin, M.D.

Title:

Chief Executive Officer

 cc: Eric W. Blanchard, Covington & Burling LLP